Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939055 | 1.00 | NAAA (0.35) | NAAAKDM4EL3MBTL1FPR2ACACB | |
| SCHEMBL12223913 | 0.97 | NAAA (0.36) | NAAAKDM4EL3MBTL1ACACBIKBKB | |
| SCHEMBL15381759 | 0.93 | NAAA (0.38) | NAAAFPR2ACACBHTR1AALOX5AP | |
| SCHEMBL15381649 | 0.93 | NAAA (0.38) | NAAAFPR2ACACBHTR1AALOX5AP | |
| SCHEMBL11939184 | 0.91 | KDM4E (0.36) | KDM4EL3MBTL1ACACBHTR1AALOX5AP | |
| SCHEMBL11939206 | 0.91 | KDM4E (0.36) | KDM4EL3MBTL1ACACBHTR1AALOX5AP | |
| SCHEMBL14922574 | 0.90 | NAAA (0.36) | NAAAFPR2ACACBHTR1AALOX5AP | |
| SCHEMBL14922552 | 0.90 | NAAA (0.40) | NAAAACACBHTR1AALOX5APFEN1 | |
| SCHEMBL15381670 | 0.90 | FPR2 (0.38) | KDM4EFPR2IKBKBALOX5APFEN1 | |
| SCHEMBL12223457 | 0.89 | NAAA (0.30) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580147-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | NAAA 4102/4885KDM4E 4164/4885L3MBTL1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.